Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Equity Ratio (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Equity Ratio for 4 consecutive years, with 0.72 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 43.11% to 0.72 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.72, a 43.11% increase, with the full-year FY2024 number at 0.46, down 10.81% from a year prior.
  • Equity Ratio was 0.72 for Q3 2025 at Century Therapeutics, down from 0.74 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.76 in Q1 2025 to a low of 0.46 in Q4 2024.
  • A 4-year average of 0.61 and a median of 0.61 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: fell 17.68% in 2023, then surged 49.26% in 2025.
  • Century Therapeutics' Equity Ratio stood at 0.62 in 2022, then dropped by 17.68% to 0.51 in 2023, then fell by 10.81% to 0.46 in 2024, then soared by 57.74% to 0.72 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Equity Ratio are 0.72 (Q3 2025), 0.74 (Q2 2025), and 0.76 (Q1 2025).